NASDAQ:ADXS Ayala Pharmaceuticals (ADXS) Stock Forecast, Price & News Add Compare Share Share Today's Range N/A50-Day Range$0.80▼$1.2352-Week Range N/AVolume5,211 shsAverage Volume1,824 shsMarket Capitalization$1.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial MediaProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media About Ayala Pharmaceuticals (NASDAQ:ADXS) StockAyala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. It is also developing proprietary Lm-based antigen delivery products for patients suffering from common cancers. The company's lead candidates under development are AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat various tumors, including desmoid tumors; and ADXS-504, a Lm-based therapy for early-stage prostate cancer. Ayala Pharmaceuticals, Inc. was founded in 2017 and is based in Monmouth Junction, New Jersey.Read More ADXS Stock News HeadlinesSeptember 29, 2023 | americanbankingnews.comAyala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.comSeptember 21, 2023 | americanbankingnews.comAyala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated by Analysts at StockNews.comOctober 1, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!August 10, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 3, 2023 | investing.comAyala Pharmaceuticals Inc (ADXS)August 1, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023July 27, 2023 | finance.yahoo.comAyala Pharmaceuticals and Biosight Enter into Definitive Merger AgreementJuly 5, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid TumorsOctober 1, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!June 5, 2023 | finance.yahoo.comUpdated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual MeetingMay 25, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual MeetingMay 23, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate UpdateMay 20, 2023 | health.usnews.comArmando AyalaApril 27, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingApril 13, 2023 | uk.finance.yahoo.comAyala Pharmaceuticals, Inc. (ADXS)April 12, 2023 | forbes.comHubei Biocause PharmaceuticalMarch 3, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Continuation of RINGSIDE Phase 2/3 Study in Desmoid Tumors Following Recommendation of Independent Data Monitoring CommitteeFebruary 10, 2023 | finance.yahoo.comAyala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022January 19, 2023 | finance.yahoo.comAdvaxis and Ayala Pharmaceuticals Complete MergerDecember 25, 2022 | finance.yahoo.comAdvaxis, Inc. (ADXS) Stock Historical Prices & Data - Yahoo FinanceOctober 20, 2022 | streetinsider.comForm 8-K Advaxis, Inc. For: Oct 18 - StreetInsider.comOctober 20, 2022 | finance.yahoo.comRedHill Biopharma Shares Surge New Treatment Patent For Its Late-Stage COVID-19 Candidate - Yahoo FinanceOctober 19, 2022 | marketscreener.comADVAXIS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure (form 8-K) - Marketscreener.comOctober 19, 2022 | benzinga.comWhy United Airlines Shares Are Trading Higher? Here Are 43 Stocks Moving In Wednesday’s Mid-Day Session - - BenzingaOctober 19, 2022 | businesswire.comAYLA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Ayala Pharmaceuticals, Inc. Is Fair to Shareholders - Business WireOctober 19, 2022 | baystreet.caAyala, Advaxis Merge - Baystreet.caOctober 19, 2022 | marketwatch.comAyala Pharmaceuticals, Advaxis to Combine in Stock Deal >AYLA ADXS - MarketWatchSee More Headlines Receive ADXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADXS Company Calendar Last Earnings9/09/2021Today10/01/2023Next Earnings (Estimated)10/02/2023Fiscal Year End10/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADXS CUSIPN/A CIK1100397 Webwww.ayalapharma.com Phone609-452-9813Fax609-452-9818EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($8.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,360,000.00 Net MarginsN/A Pretax Margin-190,238.45% Return on Equity-248.72% Return on Assets-123.57% Debt Debt-to-Equity RatioN/A Current Ratio1.13 Quick Ratio1.13 Sales & Book Value Annual Sales$250,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$13.01 per share Price / BookN/AMiscellaneous Outstanding Shares1,820,000Free Float1,805,000Market Cap$1.45 million OptionableNot Optionable Beta2.34 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Kenneth A. Berlin J.D. (Age 59)Pres, CEO & Director Mr. Igor Gitelman CPA (Age 47)CPA, M.B.A., MBA, Interim CFO & VP of Fin. Dr. Shmuel Tuvia Ph.D.Chief Scientific OfficerMs. Irit Klipper Avni M.A.VP of HRMs. Dana Gelbaum M.B.A. (Age 49)M.Sc., GM & Chief Bus. Officer Dr. Andres A. Gutierrez M.D. (Age 62)Ph.D., Exec. VP & Chief Medical Officer More ExecutivesKey CompetitorsInfinity PharmaceuticalsNASDAQ:INFIChina PharmaNYSE:CPHIAltamira TherapeuticsNASDAQ:CYTOChina SXT PharmaceuticalsNASDAQ:SXTCScopus BioPharmaNASDAQ:SCPSView All Competitors ADXS Stock - Frequently Asked Questions Should I buy or sell Ayala Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ayala Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ADXS shares. View ADXS analyst ratings or view top-rated stocks. When is Ayala Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, October 2nd 2023. View our ADXS earnings forecast. How were Ayala Pharmaceuticals' earnings last quarter? Ayala Pharmaceuticals, Inc. (NASDAQ:ADXS) posted its quarterly earnings data on Thursday, September, 9th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.02. The company had revenue of $0.25 million for the quarter. What other stocks do shareholders of Ayala Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ayala Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Anavex Life Sciences (AVXL), Vistagen Therapeutics (VTGN), Novavax (NVAX), Highpower International (HPJ), OPKO Health (OPK) and Athersys (ATHX). What is Ayala Pharmaceuticals' stock symbol? Ayala Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADXS." How do I buy shares of Ayala Pharmaceuticals? Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. How much money does Ayala Pharmaceuticals make? Ayala Pharmaceuticals (NASDAQ:ADXS) has a market capitalization of $0.00 and generates $250,000.00 in revenue each year. The company earns $-14,360,000.00 in net income (profit) each year or ($8.93) on an earnings per share basis. How can I contact Ayala Pharmaceuticals? Ayala Pharmaceuticals' mailing address is 9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ 08852, United States. The official website for the company is www.ayalapharma.com. The company can be reached via phone at 609-452-9813, via email at ir@ayalapharma.com, or via fax at 609-452-9818. This page (NASDAQ:ADXS) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.